Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease

Abstract CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kevin A. Lidberg, Andrew J. Annalora, Marija Jozic, Daniel J. Elson, Lu Wang, Theo K. Bammler, Susanne Ramm, Maria Beatriz Monteiro, Jonathan Himmelfarb, Craig B. Marcus, Patrick L. Iversen, Edward J. Kelly
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a3c201a0a7084bb899171d4e7331ae73
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a3c201a0a7084bb899171d4e7331ae73
record_format	dspace
spelling	oai:doaj.org-article:a3c201a0a7084bb899171d4e7331ae732021-12-02T13:20:22ZAntisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease10.1038/s41598-021-84194-w2045-2322https://doaj.org/article/a3c201a0a7084bb899171d4e7331ae732021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84194-whttps://doaj.org/toc/2045-2322Abstract CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators have considered CYP3A51 as active and CYP3A53 as an inactive allele. Observations of gender specific differences in CYP3A53/3 protein expression suggest additional complexity in gene regulation that may underpin an environmentally responsive role for CYP3A5 in renal function. Reconciliation of the molecular mechanism driving conditional restoration of functional CYP3A53 expression from alternatively spliced transcripts, and validation of a morpholino-based approach for selectively suppressing renal CYP3A5 expression, is the focus of this work. Morpholinos targeting a cryptic splice acceptor created by the CYP3A53 mutation in intron 3 rescued functional CYP3A5 expression in vitro, and salt-sensitive cellular mechanisms regulating splicing and conditional expression of CYP3A53 transcripts are reported. The potential for a G-quadruplex (G4) in intron 3 to mediate restored splicing to exon 4 in CYP3A53 transcripts was also investigated. Finally, a proximal tubule microphysiological system (PT-MPS) was used to evaluate the safety profile of morpholinos in proximal tubule epithelial cells, highlighting their potential as a therapeutic platform for the treatment of renal disease.Kevin A. LidbergAndrew J. AnnaloraMarija JozicDaniel J. ElsonLu WangTheo K. BammlerSusanne RammMaria Beatriz MonteiroJonathan HimmelfarbCraig B. MarcusPatrick L. IversenEdward J. KellyNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kevin A. Lidberg Andrew J. Annalora Marija Jozic Daniel J. Elson Lu Wang Theo K. Bammler Susanne Ramm Maria Beatriz Monteiro Jonathan Himmelfarb Craig B. Marcus Patrick L. Iversen Edward J. Kelly Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
description	Abstract CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators have considered CYP3A51 as active and CYP3A53 as an inactive allele. Observations of gender specific differences in CYP3A53/3 protein expression suggest additional complexity in gene regulation that may underpin an environmentally responsive role for CYP3A5 in renal function. Reconciliation of the molecular mechanism driving conditional restoration of functional CYP3A53 expression from alternatively spliced transcripts, and validation of a morpholino-based approach for selectively suppressing renal CYP3A5 expression, is the focus of this work. Morpholinos targeting a cryptic splice acceptor created by the CYP3A53 mutation in intron 3 rescued functional CYP3A5 expression in vitro, and salt-sensitive cellular mechanisms regulating splicing and conditional expression of CYP3A53 transcripts are reported. The potential for a G-quadruplex (G4) in intron 3 to mediate restored splicing to exon 4 in CYP3A53 transcripts was also investigated. Finally, a proximal tubule microphysiological system (PT-MPS) was used to evaluate the safety profile of morpholinos in proximal tubule epithelial cells, highlighting their potential as a therapeutic platform for the treatment of renal disease.
format	article
author	Kevin A. Lidberg Andrew J. Annalora Marija Jozic Daniel J. Elson Lu Wang Theo K. Bammler Susanne Ramm Maria Beatriz Monteiro Jonathan Himmelfarb Craig B. Marcus Patrick L. Iversen Edward J. Kelly
author_facet	Kevin A. Lidberg Andrew J. Annalora Marija Jozic Daniel J. Elson Lu Wang Theo K. Bammler Susanne Ramm Maria Beatriz Monteiro Jonathan Himmelfarb Craig B. Marcus Patrick L. Iversen Edward J. Kelly
author_sort	Kevin A. Lidberg
title	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
title_short	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
title_full	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
title_fullStr	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
title_full_unstemmed	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
title_sort	antisense oligonucleotide development for the selective modulation of cyp3a5 in renal disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a3c201a0a7084bb899171d4e7331ae73
work_keys_str_mv	AT kevinalidberg antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT andrewjannalora antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT marijajozic antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT danieljelson antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT luwang antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT theokbammler antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT susanneramm antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT mariabeatrizmonteiro antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT jonathanhimmelfarb antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT craigbmarcus antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT patrickliversen antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease AT edwardjkelly antisenseoligonucleotidedevelopmentfortheselectivemodulationofcyp3a5inrenaldisease
_version_	1718393230305787904

Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease

Ejemplares similares